Is there a role for oral or intravenous ascorbate (Vitamin C) in treating patients with cancer? A systematic review

Oncologist

Volumn 20, Issue 2, 2015, Pages 210-223

  Jacobs, Carmel ^a   Hutton, Brian ^b   Ng, Terry ^a   Shorr, Risa ^a   Clemons, Mark ^a,b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Ascorbate; Cancer; Chemotherapy; Quality of life; Vitamin C

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ERLOTINIB; GEMCITABINE; ICOSAPENTAENOIC ACID; MELPHALAN; METHOTREXATE; MULTIVITAMIN; PACLITAXEL; SULINDAC; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DESMOID TUMOR; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; SYSTEMATIC REVIEW; TOXICITY; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE FREE SURVIVAL; META ANALYSIS; PATHOLOGY;

ASCORBIC ACID; DIETARY SUPPLEMENTS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922705192     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0381     Document Type: Article

References (67)

1. McCormick WJ. Cancer: A collagen disease, secondary to a nutritional deficiency. Arch Pediatr 1959;76:166–171.
2. Block G. Epidemiologic evidence regarding vitamin C and cancer. Am J Clin Nutr 1991;54 (suppl):1310S–1314S.
3. Loria CM, Klag MJ, Caulfield LE et al. Vitamin C status and mortality in US adults. Am J Clin Nutr 2000;72:139–145.
4. Patterson RE, White E, Kristal AR et al. Vitamin supplements and cancer risk: The epidemiologic evidence. Cancer Causes Control 1997;8:786–802.
5. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health: A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998;7: 113–174.
6. Bjelakovic G, Nikolova D, Simonetti RG et al. Antioxidant supplements for prevention of gastrointestinal cancers: A systematic review and metaanalysis. Lancet 2004;364:1219–1228.
7. Gaziano JM, Glynn RJ, Christen WG et al. Vitamins E and C in the prevention of prostate and total cancer inmen: The Physicians’ Health Study II randomized controlled trial. JAMA 2009;301: 52–62.
8. Lin J, Cook NR, Albert C et al. Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial. J Natl Cancer Inst 2009;101:14–23.
9. Cameron E, Campbell A. The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974;9:285–315.
10. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminalhumancancer. ProcNatl Acad Sci USA 1976;73:3685–3689.
11. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538–4542.
12. Creagan ET, Moertel CG, O’Fallon JR et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687-690.
13. Moertel CG, Fleming TR, Creagan ET et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: A randomized double-blind comparison. N Engl J Med 1985;312: 137–141.
14. Du J, Cullen JJ, Buettner GR. Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim Biophys Acta 2012;1826:443–457.
15. Levine M, Conry-Cantilena C, Wang Y et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704–3709.
16. Padayatty SJ, Sun H, Wang Y et al. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004;140:533–537.
17. Huebner J, Muenstedt K, Prott FJ et al. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel) 2014;9:60–63.
18. Padayatty SJ, Sun AY, Chen Q et al. Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010;5:e11414.
19. Nutrition Business Journal. An analysis of markets, trends, competition and strategy in the U.S. dietary supplement industry: NBJ’s Supplement Business Report. Available at http://newhope360. com/site-files/newhope360.com/files/uploads/2011/10/TOCEXECSUMM110930.supp%20report %20FINAL-2.pdf. Accessed November 23, 2014.
20. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17: 1–12.
21. Wells GASB, O’Connell D, Peterson J et al. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed April 1, 2014.
22. Campbell A, Jack T, Cameron E. Reticulum cell sarcoma: Two complete ‘spontaneous’ regressions, in response to high-dose ascorbic acid therapy: A report on subsequent progress. Oncology 1991;48: 495–497.
23. Cameron E, Campbell A, Jack T. The orthomolecular treatment of cancer: III. Reticulum cell sarcoma: Double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 1975;11:387–393.
24. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. PLoSMed2009;6: e1000097.
25. Goel SAS, Mandal A, Singhal K et al. Emerging role of ascorbic acid in themanagementofadvanced breast carcinoma as a chemosensitizer. Asian J Surg 1999;22:333–336.
26. Harris HR, Bergkvist L,Wolk A.Vitamin C intake and breast cancer mortality in a cohort of Swedish women. Br J Cancer 2013;109:257–264.
27. Berenson JR, Yellin O, Woytowitz D et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen. Eur J Haematol 2009;82: 433-439.
28. Itoh H, Ikeda S, Oohata Y et al. Treatment of desmoid tumors in Gardner’s syndrome. Report of a case. Dis Colon Rectum 1988;31:459–461.
29. Ma Y, Chapman J, Levine M et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014;6:222-218.
30. Vollbracht C, Schneider B, Leendert V et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011;25:983-990.
31. Stephenson CM, Levin RD, Spector T et al. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol 2013;72: 139–146.
32. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658–3668.
33. Abou-Jawde RM, Reed J, Kelly M et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial. Med Oncol 2006;23:263–272.
34. Chang JE, Voorhees PM, Kolesar JM et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: A Wisconsin Oncology Network study. Hematol Oncol 2009;27:11–16.
35. Wu KL, Beksac M, van Droogenbroeck J et al. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2006;91:1722–1723.
36. Monti DA, Mitchell E, Bazzan AJ et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012;7: e29794.
37. Riordan HD, Casciari JJ, González MJ et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005;24:269–276.
38. Nangia SVM. Acute oxalate nephropathy from intravenous vitamin C therapy. Am J Kidney Dis 2011;57:B71.
39. Mikirova N, Casciari J, Rogers A et al. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med 2012;10:189.
40. Riordan HDR, Riordan NH, Jackson JA et al. Intravenous vitamin C as a chemotherapy agent: A report on clinical cases. P R Health Sci J 2004;23: 115–118.
41. Jackson JA, Riordan HD, Bramhall NL et al. Sixteen year history with high dose intravenous vitamin C treatment for various types of cancer and other diseases. J Orthomol Med 2002;17: 117–118.
42. Padayatty SJ, Riordan HD, Hewitt SM et al. Intravenously administered vitamin C as cancer therapy: Three cases. CMAJ 2006;174:937–942.
43. Welsh JL, Wagner BA, van’t Erve TJ et al. Pharmacological ascorbatewith gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother Pharmacol 2013;71:765-775.
44. Carr AC,Vissers MC, Cook J. Relief from cancer chemotherapy side effects with pharmacologic vitamin C. N Z Med J 2014;127:66–70.
45. Zemskov VS, Procopchuk OL, Susak YM et al. Ukrain (NSC-631570) in the treatment of pancreas cancer. Drugs Exp Clin Res 2000;26:179–190.
46. Cameron E, Campbell A. Innovation vs. quality control: An ‘unpublishable’ clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 1991;36:185–189.
47. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 1982;23: 103–113.
48. Hoffer LJ, Levine M, Assouline S et al. Phase I clinical trial of I.V. ascorbic acid in advanced malignancy. Annals Oncol 2008;19:1969–1974.
49. Takahashi H, Mizuno H, Yanagisawa A. Highdose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe 2012;1:49–53.
50. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci 2007;22:7-11.
51. Campbell A, Jack T. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J 1979;24:151–153.
52. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003;22: 118–123.
53. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115–1123.
54. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999;17:1244.
55. Soignet SL, Maslak P, Wang Z-G et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341–1348.
56. National Cancer Institute. Ctc v2.0. 1999. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed April 20, 2014.
57. CONSORT. The CONSORT statement. 2010. Available at http://www.consort-statement.org/consort-statement/overview0/. Accessed April 2, 2014.
58. Kobayashi K, Takeda F, Teramukai S et al. A cross-validation of the European Organization for Research and Treatment of Cancer qlq-c30 (EORTC qlq-c30) for Japanese with lung cancer. Eur J Cancer 1998;34:810–815.
59. Kato J, Nagahara A, Iijima K et al. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan. J Gastroenterol Hepatol 2008;23 (suppl 2):S268–S272.
60. Farrar JT, Young JP Jr., LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–158.
61. Wilson MK, Baguley BC,Wall C et al. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol 2014;10: 22–37.
62. Fritz HWL, Flower G, Kirchner L et al. Intravenous vitamin C and cancer: A systematic review. Poster presented at: Applied Research in Cancer Control; May 12, 2014; Toronto, ON, Canada.
63. Graumlich JF, Ludden TM, Conry-Cantilena C et al. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 1997;14:1133–1139.
64. Bram S, Froussard P, GuichardMet al. Vitamin Cpreferential toxicity formalignantmelanomacells. Nature 1980;284:629–631.
65. Casciari JJ, Riordan NH, Schmidt TL et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 2001;84:1544–1550.
66. Lawton JM, Conway LT, Crosson JT et al. Acute oxalate nephropathy after massive ascorbic acid administration. Arch InternMed 1985;145:950–951.
67. Campbell GD Jr., Steinberg MH, Bower JD. Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 1975;82: 810.